The Year Ahead: Controversial NDAs Could Entangle FDA In ‘08; Where Are The Oncologics?
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Looking ahead at FDA’s review calendar for 2008, the agency will be wrestling with several enigmatic decisions as it considers applications for fibromyalgia and chronic fatigue syndrome, controversial diseases with nebulous definitions and diagnoses.